Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Anruixi (zuberitamab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Zhejiang Hisun

Drug class:

CD20 inhibitor

Related drugs:

‹

SIBP-02 (rituximab biosimilar) (0)

TL011 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

rituximab (174)

obinutuzumab (68)

epcoritamab-bysp (11)

ublituximab-xiiy (7)

rituximab-pvvr (6)

rituximab-abbs (6)

rituximab/hyaluronidase (5)

Rixathon (rituximab biosimilar) (4)

ibritumomab tiuxetan (3)

mosunetuzumab-axgb (2)

rituximab-arrx (2)

glofitamab-gxbm (1)

TQB2303 (rituximab biosimilar) (1)

Ritucad (rituximab biosimilar) (1)

AcellBia (rituximab biosimilar) (0)

Avetux (rituximab biosimilar) (0)

BI 695500 (rituximab biosimilar) (0)

CIMAbior (rituximab biosimilar) (0)

DI Leu16 IL-2 (0)

GB241 (rituximab biosimilar) (0)

Halpryza (rituximab biosimilar) (0)

Hanlikon (rituximab biosimilar) (0)

JHL1101 (rituximab biosimilar) (0)

Kikuzubam (rituximab biosimilar) (0)

MK-8808 (rituximab biosimilar) (0)

MabionCD20 (rituximab biosimilar) (0)

Mabtas (rituximab biosimilar) (0)

Novex (rituximab biosimilar) (0)

ocrelizumab (0)

Reditux (rituximab biosimilar) (0)

Retuxira (rituximab biosimilar) (0)

SAIT101 (rituximab biosimilar) (0)

SIBP-02 (rituximab biosimilar) (0)

TL011 (rituximab biosimilar) (0)

TG20 (rituximab biosimilar) (0)

›